|1.||Grdina, David J: 11 articles (02/2013 - 01/2002)|
|2.||Murley, Jeffrey S: 11 articles (02/2013 - 01/2002)|
|3.||Kataoka, Yasushi: 8 articles (01/2011 - 01/2002)|
|4.||Li, Jian Jian: 4 articles (02/2013 - 11/2004)|
|5.||Hainaut, Pierre: 4 articles (06/2005 - 03/2002)|
|6.||Weichselbaum, Ralph R: 3 articles (02/2013 - 01/2002)|
|7.||Morgan, William F: 3 articles (02/2010 - 04/2007)|
|8.||Cassatt, David R: 3 articles (03/2005 - 12/2002)|
|9.||Kifle, Gizachew: 3 articles (03/2005 - 12/2002)|
|10.||Bachy, Christine M: 3 articles (03/2005 - 12/2002)|
05/01/2008 - "The ability of WR1065 to induce a persistent elevated radiation resistance in malignant cells, however, suggests a new potential concern regarding the issue of tumor protection in patients exposed to thiol-containing drugs."
05/05/2005 - "This method should be particularly valuable in translating the kinetic-dynamic relationship of WR-1065 in preclinical models to that in cancer patients."
03/01/2005 - "WR-1065 did not accumulate in tissues or tumor upon repeated administration. "
01/01/2004 - "The liver/tumor concentration ratios of WR-1065 following portal dosing were up to 8-fold higher than the ratio following systemic administration. "
01/01/2004 - "The WR-1065 tumor portal dosing AUC15-60 was 40% of systemic dosing, and tumor concentrations following portal dosing were one-fifth of that following systemic dosing. "
|2.||Chromosome Aberrations (Chromosome Abnormalities)
01/01/1993 - "Concentration-dependent protection against X-ray-induced chromosome aberrations in human lymphocytes by the aminothiol WR-1065."
01/01/1993 - "Neither proliferation kinetics nor baseline frequencies of aberrations or MN were affected in nonirradiated cultures incubated in WR-1065 for up to 45 min. Radiation-induced chromosome aberrations and MN varied inversely as a logarithmic function of thiol concentration. "
01/01/1993 - "G0 lymphocytes were incubated for 30 min in medium containing 1-12 mM WR-1065, exposed to 0 or 3.1 Gy 220-kV X rays, washed, and cultured for evaluations of chromosome aberrations and micronuclei (MN). "
01/01/1993 - "We measured the efficiency of WR-1065 in modifying the induction of chromosome aberrations by X rays in human lymphocytes. "
12/10/1995 - "The radioprotectors cysteamine (CSM) and WR-1065 have been shown in previous studies to potentiate the induction of micronuclei and chromosome aberrations by BLM in Go human lymphocytes. "
12/15/2008 - "These results confirm that WR-1065 is protective against both low- and high-LET radiation-induced genomic instability in surviving cells."
12/15/2008 - "Lower, nontoxic concentrations of WR-1065 did not protect cells from death; however, it was effective in significantly decreasing delayed genomic instability in the progeny of irradiated cells. "
02/01/2010 - "We hypothesize that hyperstimulation of HR pathways plays a mechanistic role in radiation-induced genomic instability and that, in part, WR-1065 exerts it radioprotective effect through suppression of the HR pathway. "
12/15/2008 - "When added 30 min before irradiation and in high concentrations, WR-1065 protected cells from immediate radiation-induced effects as well as from delayed genomic instability. "
12/15/2008 - "In this study we used WR-1065, the active metabolite of amifostine, to determine how protection from direct effects of high- and low-LET radiation exposure influences genomic stability. "
|5.||Human Influenza (Influenza)
|5.||lissamine rhodamine B (sulforhodamine B)
|7.||Transcription Factors (Transcription Factor)
|1.||Drug Therapy (Chemotherapy)